Diabetes mellitus and responsiveness of endometrial hyperplasia and early endometrial cancer to conservative treatment

Gynecol Endocrinol. 2019 Nov;35(11):932-937. doi: 10.1080/09513590.2019.1624716. Epub 2019 Jun 5.


Objective: The conservative treatment of endometrial hyperplasia without atypia (HWA), atypical endometrial hyperplasia (AH/EIN) and early endometrioid carcinoma (EEC) is based on progestins. We aimed to assess whether diabetes mellitus affects the responsiveness of HWA, AH/EIN and EEC to conservative treatment, through a systematic review and meta-analysis. Study design: Electronic databases were searched for studies assessing the outcome of conservative treatment in HWA, AH/EIN and EEC, stratified based on the diagnosis of diabetes mellitus. The association of diabetes mellitus with treatment failure was assessed by using odds ratio (OR). A p-value < .05 was considered significant. The risk of publication bias was assessed by using a funnel plot. A subgroups analyses was performed based on histologic diagnosis of benignity (HWA) or premalignancy/malignancy (AH/EIN or EEC). Results: Six studies with 876 patients (383 HWA, 365 AH/EIN and 128 EEC) were included. Overall, diabetes mellitus was not associated with outcome of treatment (OR = 1.20; p = .62). The association was not significant in both the HWA subgroup (OR = 0.95; p = .93) and in AH/EIN and EEC subgroup (OR = 1.43; p = .46). There was no significant risk of publication bias. Conclusions: Diabetes mellitus does not affect the outcome of conservative treatment in HWA, AH/EIN and EEC.

Keywords: Endometrial hyperplasia; diabetes; endometrial intraepithelial neoplasia; endometrioid carcinoma; fertility-sparing.

Publication types

  • Review

MeSH terms

  • Conservative Treatment*
  • Diabetes Complications / therapy*
  • Endometrial Hyperplasia / complications
  • Endometrial Hyperplasia / therapy*
  • Endometrial Neoplasms / complications
  • Endometrial Neoplasms / therapy*
  • Female
  • Humans